These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15981717)

  • 1. Morphological imaging in the localization of neuroendocrine gastroenteropancreatic tumors found by somatostatin receptor scintigraphy.
    Saga T; Shimatsu A; Koizumi K; Ichikawa T; Yamamoto K; Noguchi S; Doi R; Ishibashi M; Machinami R; Nakamura K; Sakahara H; Endo K
    Acta Radiol; 2005 May; 46(3):227-32. PubMed ID: 15981717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
    Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
    J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors.
    Bäder M; Koppenhagen K
    Recent Results Cancer Res; 1996; 142():137-62. PubMed ID: 8893340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
    Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
    Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
    Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
    Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
    Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
    Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
    Kumbasar B; Kamel IR; Tekes A; Eng J; Fishman EK; Wahl RL
    Abdom Imaging; 2004; 29(6):696-702. PubMed ID: 15162235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
    Jamar F; Fiasse R; Leners N; Pauwels S
    J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system.
    Biliotti G; Martini F; Vaggelli L; Messerini L; Colagrande S; Pupi A; Seghi P
    Tumori; 2006; 92(2):170-4. PubMed ID: 16724698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
    Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
    Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients.
    Gotthardt M; Dirkmorfeld LM; Wied MU; Rinke A; Béhé MP; Schlieck A; Höffken H; Alfke H; Joseph K; Klose KJ; Behr TM; Arnold R
    Digestion; 2003; 68(2-3):80-5. PubMed ID: 14581764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polish diagnostic and therapeutic guidelines in gastroenteropancreatic neuroendocrine tumors (GEP NET)].
    Kos-Kudła B;
    Endokrynol Pol; 2006; 57(3):267-72. PubMed ID: 17111342
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
    Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
    Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
    Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
    Pauwels S; Leners N; Fiasse R; Jamar F
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.